home.aspx

 
. home.aspx home.aspx

ARCHIVED NEWS


    AI TEST DETECTS EARLY SIGNS OF DEMENTIA

    Sep 20, 2018

    A pioneering artificial intelligence (AI) computer test can help detect whether individuals are in the early stages of dementia. Through a series of questions with an interactive on-screen avatar, a computer programme designed by researchers from Osaka University and Nara Institute of Science and Te...


    READ MORE

    https://Pharmaceutical.report/news-article.aspx?ID=19701970

    2 NATURE STUDIES ILLUSTRATE THE ABILITY OF AI TO DIVE DEEPER INTO MEDICAL IMAGES AND PATHOLOGY

    Sep 20, 2018

    In two separate studies, researchers have used machine learning to train computers to spot and classify cells as well as their hidden, internal structures and DNA by using images alone. For a specific example, NYU researchers using an open source, the deep neural network developed by Google have tau...


    READ MORE

    https://Pharmaceutical.report/news-article.aspx?ID=19711971

    TRIAL TAKES FIBROGEN’S RENAL ANEMIA DRUG CLOSER TO EU FILING

    Sep 20, 2018

    FibroGen has staked another claim to market for a new class of oral therapies for anemia associated with chronic kidney disease (CKD), after reporting a positive phase 3 trial. Roxadustat currently leading the pack in the hypoxia-inducible factor (HIF) stabilizer category met its objectives in the A...


    READ MORE

    https://Pharmaceutical.report/news-article.aspx?ID=19721972

    NEW FASTER, CHEAPER, BETTER TEST PLATFORM FOR NUCLEIC ACID IDENTIFICATION OF DISEASES

    Sep 20, 2018

    At the National University of Singapore, scientists have developed a portable, point-of-care nucleic acid test platform that can be used to diagnose a variety of diseases. It comes in the form of a cartridge that does not need to be kept refrigerated or handled specially in any other way and once us...

    NATIONAL UNIVERSITY OF SINGAPORE
    READ MORE

    https://Pharmaceutical.report/news-article.aspx?ID=19731973

    RESEARCHERS IDENTIFY A NEW CAUSE OF CHILDHOOD MITOCHONDRIAL DISEASE

    Sep 20, 2018

    A rapid genetic test developed by Newcastle researchers has identified the first patients with inherited mutations in a new disease gene. The team of medics and scientists, led by the Wellcome Centre for Mitochondrial Research at Newcastle University, found four children with defects in a building b...


    READ MORE

    https://Pharmaceutical.report/news-article.aspx?ID=19741974

    STUDY IDENTIFIES STEM CELL THAT GIVES RISE TO NEW BONE AND CARTILAGE IN HUMANS

    Sep 20, 2018

    A decade-long effort led by Stanford University School of Medicine scientists has been rewarded with the identification of the human skeletal stem cell. The cell, which can be isolated from human bone or generated from specialized cells in fat, gives rise to progenitor cells that can make new bone, ...

    STANFORD UNIVERSITY MEDICAL CENTER
    READ MORE

    https://Pharmaceutical.report/news-article.aspx?ID=19751975

    EXICURE PLANS CHECKPOINT COMBO AFTER TLR9 DRUG CLEARS EARLY TEST

    Sep 20, 2018

    Exicure is set to move toll-like receptor 9 (TLR9) agonist AST-008 into a phase 1b/2 trial after getting a look at data from healthy volunteers. The first-in-human clinical trial suggested that AST-008 is safe, tolerable and boosts cytokine levels.
    AST-008, Exicure’s lead asset, is base...


    READ MORE

    https://Pharmaceutical.report/news-article.aspx?ID=19761976

    TRUVADA RULING COULD ALLOW CHEAP HIV PREVENTION IN THE UK

    Sep 19, 2018

    Cheap copies of Gilead’s HIV drug Truvada, which can also be used to reduce the risk of people becoming infected, could be available in the UK following a court ruling. Truvada (tenofovir disoproxil+emtricitabine) is used as the backbone of many HIV combination therapies, and the decision pave...


    READ MORE

    https://Pharmaceutical.report/news-article.aspx?ID=19691969

TRENDING NEWS


    JOHNSON & JOHNSON TAKES $630M HIT ON RSV DRUG BOUGHT WITH ALIOS

    Oct 18, 2018

    Four years ago, Johnson & Johnson splashed out $1.75 billion to take control of antiviral specialist Alios, but the lead drug from that deal now seems to be in trouble. J&J revealed in August that phase 2b trials of respiratory syncytial virus (RSV) drug lumicitabine—also known as AL-8...


    READ MORE

    https://www.fiercebiotech.com/biotech/j-j-takes-630m-hit-rsv-drug-bought-alios2053

    PFIZER ANNOUNCES WORLDWIDE JOB CUTS AS PART OF RESTRUCTURE

    Oct 18, 2018

    Pfizer is planning thousands of jobs cuts worldwide as part of a round of cost-cutting as incoming CEO Albert Bourla prepares to take the helm. Bourla has been promoted from his role as the chief operating officer and will replace Ian Read as CEO on 1st January. Pfizer already announced a plan in Ju...


    READ MORE

    https://pharmaphorum.com/news/pfizer-announces-worldwide-job-cuts-as-part-of-restructure/2054

    NOVARTIS TO BUY CANCER DRUG FIRM ENDOCYTE FOR $2.1BN

    Oct 18, 2018

    Novartis has announced plans to buy cancer drug firm Endocyte for $2.1 billion cash. The Swiss pharma giant is buying the US-based Endocyte to expand its radiopharmaceuticals business. News of the plans sent Endocyte’s shares rocketing by 49.74% to $23.30 in pre-market trading The Endocyte acq...


    READ MORE

    https://pharmaphorum.com/news/novartis-to-buy-cancer-drug-firm-endocyte-for-2-1bn/2055

    GILEAD, AELIX ALLY TO TRIAL HIV-SUPPRESSING COMBINATION

    Oct 18, 2018

    Gilead has teamed up with Aelix Therapeutics to trial a combination designed to free people with HIV from the need to take antiretroviral drugs. The planned clinical trial will test Gilead’s TLR7 agonist in combination with Aelix’s T-cell vaccine. Gilead began testing the TLR7 agonist, v...


    READ MORE

    https://www.fiercebiotech.com/biotech/gilead-aelix-ally-to-trial-hiv-suppressing-combination2056

    IMPROVING CANCER IMMUNOTHERAPY BY CONTROLLING RNA EXPRESSION

    Oct 18, 2018

    Gene therapy has become one of the hottest areas of biotech research. Some gene therapies, like Spark Therapeutics’ eye drug Luxturna, deliver healthy genes to replace mutated ones, while others, such as Alnylam Pharmaceuticals’ RNA interference therapy Onpattro, work by silencing diseas...


    READ MORE

    https://www.fiercebiotech.com/research/controlling-rna-expression-to-make-cancer-immunotherapy-more-precise2057

    RESEARCHERS CURE DRUG-RESISTANT INFECTIONS WITHOUT ANTIBIOTICS

    Oct 17, 2018

    Biochemists, microbiologists, drug discovery experts, and infectious disease doctors have teamed up in a new study that shows antibiotics are not always necessary to cure sepsis in mice. Instead of killing causative bacteria with antibiotics, researchers treated infected mice with molecules that blo...

    CASE WESTERN RESERVE UNIVERSITY
    READ MORE

    https://medicalxpress.com/news/2018-10-drug-resistant-infections-antibiotics.html2048

    AI COULD TRANSFORM CARE FOR OLDER PEOPLE, ROBOT TELLS MPS

    Oct 17, 2018

    A House of Commons committee questioned a humanoid robot, Pepper, to see how artificial intelligence (AI) and robotics can be used to help care for older people. Pepper is currently based at Middlesex University and works with final year students on robotics, psychology, biomedicine, and education.<...


    READ MORE

    https://pharmaphorum.com/news/ai-could-transform-care-for-older-people-robot-tells-mps/2049

    US BLOOD PRESSURE DRUG PRICE DOUBLES FOLLOWING SHORTAGES

    Oct 17, 2018

    Prices of the generic blood pressure drug valsartan rose more than any other in the US following a recall of much of the drug’s supply, according to press reports. The Chinese ingredient manufacturer Zhejiang Huahai Pharmaceuticals recalled valsartan in July after finding traces of a probable ...


    READ MORE

    https://pharmaphorum.com/news/us-blood-pressure-drug-price-doubles-following-shortages/2050

    PFIZER’S TALZENNA PARP BREAST CANCER DRUG APPROVED IN US

    Oct 17, 2018

    The US drug regulator has approved Pfizer’s breast cancer medicine Talzenna (talazoparib) for patients with a certain mutation. The drug was approved by the US Food and Drug Administration (FDA) for patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2‑negativ...


    READ MORE

    https://pharmaphorum.com/news/pfizers-talzenna-parp-breast-cancer-drug-approved-in-us/2051

    MEDICAL MANAGEMENT OF OPIOID-INDUCED CONSTIPATION DIFFERS FROM OTHER FORMS OF CONDITION

    Oct 17, 2018

    Traditional laxatives are recommended as first-line agents to treat patients with a confirmed diagnosis of opioid-induced constipation (OIC), according to a new guideline from the American Gastroenterological Association (AGA). If an adequate trial of laxatives results in suboptimal symptom control,...


    READ MORE

    https://medicalxpress.com/news/2018-10-medical-opioid-induced-constipation-differs-condition.html2052

    SENSYNE’S GESTATIONAL DIABETES AI APP LAUNCHES ON THE NHS

    Oct 16, 2018

    Artificial intelligence company Sensyne Health has launched a new app that helps women manage gestational diabetes, and five NHS hospitals have already signed up. GDm-Health is a tool enabling remote management of gestational diabetes, reducing the need for expectant mothers to attend additional med...

    RICHARD STAINES
    READ MORE

    https://pharmaphorum.com/news/sensynes-gestational-diabetes-ai-app-launches-on-the-nhs/2043

    DEEP LENS UNVEILS CANCER DIAGNOSIS AI TECH FOR PATHOLOGISTS

    Oct 16, 2018

    Digital pathology startup Deep Lens has unveiled an artificial intelligence (AI) platform that will enable pathologists to diagnose cancer patients more swiftly and accurately. The Ohio-based company has secured early funding worth $3.2m for Virtual Imaging for Pathology Education and Research (VIPE...


    READ MORE

    https://pharmaphorum.com/news/deep-lens-unveils-cancer-diagnosis-ai-tech-for-pathologists/2044

    GE HEALTHCARE UNVEILS NEW AUTOMATED BREAST ULTRASOUND FOR DENSE BREASTS

    Oct 16, 2018

    GE Healthcare is unveiling its brand new Invenia Automated Breast Ultrasound (ABUS) 2.0 in the U.S. It is the only FDA approved “ultrasound supplemental breast screening technology,” which allows for spotting of cancerous lesions within dense breast tissue, according to GE. Since dense b...

    GE HEALTHCARE
    READ MORE

    https://www.medgadget.com/2018/10/ge-healthcare-unveils-new-automated-breast-ultrasound-for-dense-breasts.html2045

    NEW TEST RAPIDLY IDENTIFIES ANTIBIOTIC-RESISTANT SUPERBUGS

    Oct 16, 2018

    When you get sick, you want the right treatment fast. But certain infectious microbes are experts at evading the very anti-bacterial drugs designed to fight them. A simple and inexpensive new test developed by UC Berkeley researchers can diagnose patients with antibiotic-resistant strains of bacteri...

    UNIVERSITY OF CALIFORNIA - BERKELEY
    READ MORE

    https://phys.org/news/2018-10-rapidly-antibiotic-resistant-superbugs.html2046

    MICROLAPAROSCOPIC ROBOTIC SURGERIES NOW CLEARED ON TRANSENTERIX SENHANCE SYSTEM

    Oct 16, 2018

    TransEnterix, the maker of the Senhance robotic surgical system, won FDA clearance for its new 3-millimeter line of instruments, as well as some more 5 mm instruments. At only 3 mm in diameter, the new instruments make it possible to use the Senhance system for micro-laparoscopic surgeries with inci...

    TRANSENTERIX
    READ MORE

    https://www.medgadget.com/2018/10/microlaparoscopic-robotic-surgeries-now-cleared-on-transenterix-senhance-system.html2047

    HIFIBIO BUYS UP H-IMMUNE, JOINING FORCES TO ‘COMBAT CANCER’

    Oct 15, 2018

    HiFiBiO Therapeutics has had a busy year, as pacts and raises abound, and it’s showing no signs of slowing down as it gets its checkbook out for an unusual French spinout. The company in its crosshairs is H-Immune which, back in 2016, was spun out of the French Atomic Energy Commission, and fo...

    BEN ADAMS
    READ MORE

    https://www.fiercebiotech.com/biotech/hifibio-buys-up-h-immune-joining-forces-to-combat-cancer2038

SPOTLIGHT

Medsun Pharma is a Manufacturer of Pharmaceutical products. We are having world class and strong quality frameworks to guarantee that every one of the items fabricated is reliably protected and of good quality. Our point is to convey most elevated quality items at moderate costs. The organization ha

RESOURCES

Events